Shop IGF1-LR3 1mg online

IGF1-LR3 1mg is a peptide hormone that has been studied extensively in both animals and in vitro models. It is a synthetic variant of insulin-like growth factor 1 (IGF1), which is naturally produced by the body.

IGF1-LR3 is commonly used in animal models to explore the physiological impacts of IGF-1, despite differences in IGF-1 peptide sequences between humans and animals. IGF1-LR3 has 83 amino acids, with an extra 13 amino acids at the N-terminus, compared to the naturally occurring human or sheep IGF-1. IGF1 LR3 has been investigated for its potential use in a variety of medical conditions, such as muscle wasting, osteoporosis, and growth hormone deficiencies.

In a study, pregnant sheep in late gestation were given an intravenous infusion of IGF1-LR3 or saline for one week and then underwent a metabolic study to measure various parameters related to fetal growth and nutrient uptake. The results showed that while IGF1-LR3 increased the weight of some fetal organs and had a positive effect on myoblast proliferation in skeletal muscle, it did not significantly affect the fetal weight or increase nutrient transfer to the fetus. Instead, it is suggested that IGF1-LR3 may promote fetal organ-specific growth by efficiently utilizing available nutrients.¹

In another study, researchers explored the effect of IGF1-LR3 on intestinal growth in mice. They found that when administered via an osmotic pump, IGF1-LR3 has a similar effect on the small intestine as IGF-I but with a stronger impact on mucosal cellularity. These findings suggest that IGF1-LR3 may be a more effective option for promoting the growth and repair of intestinal cells, although further research is needed to fully evaluate the potential benefits and risks associated with its use in the context of intestinal health.²

Furthermore, researchers investigated the potential of IGF1-LR3 in preventing muscle wasting in a mouse model of cancer-associated cachexia. In vitro and in vivo experiments were conducted to explore the efficacy of ALK4/5 receptor (a family of conserved serine/threonine kinase receptors that bind about 30 different ligands) blockers and IGF1-LR3 in preventing muscle wasting. In vitro studies on skeletal muscle cells showed that IGF1-LR3 treatment increased the differentiation index and mean nuclei count. In vivo experiments revealed that GW788388, an ALK4/5 receptor blocker, was effective in preventing the loss of body weight and muscle wasting. However, IGF1-LR3 treatment limited the loss of muscle mass but accelerated tumor growth. The study suggests that IGF1-LR3 may have the potential to prevent muscle wasting in cancer cachexia, but further investigation is needed to balance the benefits against the risk of tumor growth.

References: 1. Stremming J et al. Sheep recombinant IGF-1 promotes organ-specific growth in fetal sheep. Front Physiol. 2022;13:954948. 2. MacDonald RS. The role of insulin-like growth factors in small intestinal cell growth and development. Horm Metab Res. 1999 Feb-Mar;31(2-3):103-13. 3. Levolger S et al. Inhibition of activin-like kinase 4/5 attenuates cancer cachexia associated muscle wasting. Sci Rep. 2019 Jul 8;9(1):9826. 4.